Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationLymphoma
Indication DetailsTreat lymphoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today